Ceryx Medical acquires $15 million for the development of innovative heart failure treatment technology
Ceryx Medical, a UK-based medtech innovator, has successfully closed a new funding round, bringing the company's total raised to $15 million. This significant investment will accelerate the development of a groundbreaking, permanent bioelectronic pacemaker designed to provide long-term support for patients with chronic heart failure.
The permanent pacemaker, which is currently undergoing clinical evaluation, is distinguished from conventional pacemakers by its ability to mimic the body's natural modulation of heart rhythms, delivering real-time, biomimetic pacing that adapts to the patient's physiological needs. This innovative approach aims to offer a more natural and effective treatment for heart failure.
Stuart Plant, CEO of Ceryx Medical, stated that the investment is a strong endorsement of the company's team, technology, and vision. Early clinical evaluation of their lead product, a temporary cardiac pacing device, has shown promising results in enhancing patient recovery following cardiac surgery, which supports the potential of their permanent solution.
Key potential benefits for chronic heart failure patients include improved cardiac function, long-term support designed to better mimic natural heart rhythms, and enhanced patient outcomes compared to traditional pacemakers by potentially reducing symptoms and improving quality of life.
Ceryx Medical’s technology is a product of collaboration between researchers from the Universities of Bristol and Bath in the UK, and the University of Auckland in New Zealand. The recent investment by top-tier investors underscores the confidence in this technology to redefine the treatment landscape for heart failure through intelligent bioelectronic systems.
The funding round was supported by leading investors including BGF, Parkwalk Advisors, Development Bank of Wales (DBW), and BBI. The focus of Ceryx Medical's work is on revolutionizing cardiac care with intelligent, adaptive pacing technology. The new funding will expedite the development of Ceryx's second product: a permanent, physiologically responsive pacemaker for patients with chronic heart failure.
Ceryx Medical continues to collaborate with academic and clinical partners to translate scientific advancements into clinical outcomes. With this latest funding, the company is one step closer to bringing its revolutionary heart failure treatment to patients worldwide.
[1] Ceryx Medical. (n.d.). Retrieved from https://www.cerixmedical.com/ [2] Ceryx Medical raises $15m to develop physiologically responsive pacemaker. (2021, March 23). Retrieved from https://www.pharmatimes.com/news/cerix_medical_raises_15m_to_develop_physiologically_responsive_pacemaker_1377867 [3] Ceryx Medical's temporary cardiac pacing device shows promising results. (2021, March 23). Retrieved from https://www.pharmatimes.com/news/cerix_medicals_temporary_cardiac_pacing_device_shows_promising_results_1377866
- This significant investment in Ceryx Medical, a UK-based medtech innovator, will drive the advancement of science in the field of digital health, focusing on revolutionizing cardiac care with technology that offers intelligent, adaptive pacing for patients with chronic medical-conditions like heart failure.
- The new funding will aid Ceryx Medical in expanding their health-and-wellness product line, expediting the development of a permanent, physiologically responsive pacemaker that promises improved cardiovascular-health outcomes for patients, potentially reducing symptoms and enhancing overall quality of life.
- The financial backing from top-tier investors underscores their belief in the potential of Ceryx Medical's technology to redefine the medical-conditions landscape, specifically for heart failure, through the application of intelligent bioelectronic systems that align with the principles of health-and-wellness and cardiovascular-health.
